Potential adverse reactions during crizotinib treatment

Crizotinib, a tyrosine kinase inhibitor (TKI) targeting ALK, ROS1, and MET mutations, has shown significant efficacy in the treatment of certain types of non-small cell lung cancer. However, similar to other targeted therapy drugs, crizotinib may also cause a series of adverse reactions during treatment, which requires patients and doctors to pay close attention.

Some patients may experience digestive discomfort such as nausea, diarrhea, and vomiting while taking crizotinib. These symptoms are usually temporary, but if they continue to worsen, they may affect the patient's nutritional intake and overall health. In addition, vision changes are also one of the common side effects of crizotinib, including blurred vision, diplopia, etc. These symptoms may cause inconvenience to patients’ daily life.

In addition to the common reactions mentioned above, crizotinib may also cause more serious side effects. For example, some patients may develop cardiovascular system problems such as high blood pressure or arrhythmias. These situations require immediate medical attention to ensure the patient's safety. At the same time, respiratory system reactions, such as difficulty breathing or coughing, may also be caused by the irritation of the lungs by the drug and need to be treated in time.

In addition, crizotinib may also have certain effects on liver and kidney function. During treatment, doctors will regularly monitor the patient's liver and kidney function to ensure the safety of the drug. If you have symptoms of abnormal liver function such as darkened urine, fatigue, or abnormal kidney function such as difficulty urinating, you should inform your doctor immediately.

Although crizotinib is excellent in treating ALK-mutated non-small cell lung cancer, the frequency and severity of adverse reactions vary among individuals. Therefore, during the treatment process, patients should pay close attention to their own reactions and communicate with their doctors in a timely manner.